Format

Send to

Choose Destination
Radiother Oncol. 2015 Feb;114(2):155-60. doi: 10.1016/j.radonc.2014.12.003. Epub 2015 Jan 9.

Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases.

Author information

1
Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: mettfode@rm.dk.
2
Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: hoyer@aarhus.rm.dk.

Abstract

BACKGROUND AND PURPOSE:

To establish a model to predict survival after SBRT for oligo-metastases in patients considered ineligible for surgical resection (SR) and radiofrequency ablation (RFA).

MATERIAL AND METHODS:

Overall survival (OS) rates were estimated in 321 patients treated for 587 metastases with SBRT over 13years. Patients were treated for a variety of metastasis types with colorectal cancer (CRC) being the most frequent (n=201).

RESULTS:

With a median follow-up time of 5.0years, the median OS was 2.4years (95% CI 2.3-2.7) and the survival rates were 80%, 39%, 23% and 12% at 1, 3, 5 and 7.5years after SBRT, respectively. WHO performance status (PS) (0-1) (HR 0.49; p<0.001), solitary metastasis (HR 0.75; p=0.049), metastasis ⩽30mm (HR 0.53; p<0.001), metachronous metastases (HR 0.71; p=0.02) and pre-SBRT chemotherapy (HR 0.59; p<0.001) were independently related to favorable OS. Median OS rates were 7.5, 2.8, 2.5, 1.7 and 0.8years with 0, 1, 2, 3, ⩾4 unfavorable prognostic factors, respectively. The treatment-related morbidity was moderate. However, three deaths were possibly treatment-related.

CONCLUSION:

Prognostic factors may predict long-term survival in patients with oligo-metastases treated with SBRT.

KEYWORDS:

Oligo-metastases; Prognostic factors; Stereotactic body radiotherapy; Survival

PMID:
25583567
DOI:
10.1016/j.radonc.2014.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center